Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Oric Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals Adds 1.1 Million Shares to Inducement Equity Plan

Neutral Impact 2 of 5 shareholder Written later

ORIC Pharmaceuticals' board approved an amended and restated 2022 Inducement Equity Incentive Plan effective July 28, 2026, adding 1,100,000 shares for a total of 3,350,000 shares reserved for equity awards. The plan was adopted without stockholder approval under Nasdaq rules and is limited to inducement grants to new hires or acquisition-related awards, so it adds to potential future share issuance.

Key points

  • Board approved an additional 1,100,000 shares, bringing the total reserved under the Inducement Plan to 3,350,000 shares of common stock.
  • Approved effective July 28, 2026, and adopted without stockholder approval under Nasdaq Listing Rules.
  • Awards may be granted only to individuals not previously employees or non-employee directors, as an inducement to employment or, where permitted, in connection with a merger or acquisition.
  • The full plan is filed as Exhibit 10.1 to the 8-K.

The filing

CompanyOric Pharmaceuticals, Inc. (ORIC)
Form8-K, current report
Filed with the SECJul 30, 2026, 4:49 PM ET
Accession number0001193125-26-326309

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.